Epizyme Reports Positive Interim Data

Shares of Epizyme were down almost 15% pre-market Wednesday even though the biopharmaceutical firm reported positive interim data from a phase 2 clinical trial of tazemetostat to treat relapsed or refractory patients with follicular lymphoma (FL), or diffuse large B-cell lymphoma (DLBCL) grouped by EZH2 mutational status.

“I believe that tazemetostat may play a significant role in disease management for my patients, and am particularly excited by the impact observed in patients with follicular lymphoma,” said Franck Morschhauser, lead investigator of the study. “Tazemetostat has demonstrated a uniquely tolerable safety profile, and I look forward to further exploring its full benefit in patients with relapsed or refractory FL and DLBCL as the data mature.”

By Stephen Holmes